培哚普利对充血性心力衰竭患者红细胞超氧化物歧化酶活力和血浆总抗氧化能力的影响

The effect of perindopril on plasma TAC level and erythrocyte SOD activity in patients with congestive heart failure

目的 :探讨血管紧张素转换酶抑制剂 (ACEI)对体内抗氧化状态的影响。方法 :采用分光光度计测定红细胞超氧化物歧化酶 (SOD)活力和血浆总抗氧化能力 (TAC)。观察了 6 7例充血性心力衰竭 (CHF)患者口服培哚普利后血浆TAC和SOD活力的改变 ,并与依那普利进行比较。结果 :两治疗组CHF患者基础红细胞SOD活力、血浆TAC水平低于健康对照组 (P <0 .0 1) ;服药后 4周 ,依那普利组和培哚普利组红细胞SOD活力、血浆TAC水平升高 (P <0 .0 5 ) ,8周后进一步升高 (P <0 .0 1)。结论 :CHF患者的抗氧化能力低下 ,依那普利和培哚普利均能提高CHF患者的抗氧化能力 。

Objective:This study investigate the changes of plasma TAC level and erythrocyte SOD activity in patients with congestive heart failure (CHF) after administration of angiotensin converting-enzyme inhibitor(ACEI).Methods:Plasma TAC level and erythrocyte SOD activity were measured by using spectrophotometer.Results:The basic levels of plasma TAC and erythrocyte SOD activity in patients with CHF were lower than that in control group(P< 0.01). Plasma TAC and erythrocyte SOD activity in perindopril group and enalaprol group increased significantly 4 week after administration(P< 0.05) and rose more remarkably 8 week after administration(P< 0.01). Conclusion:These patients with CHF have lower antioxidative ability. ACEIs such as Perindopril and Enalaprol can promote the antioxidative ability and play a beneficial role in protecting from deterioration of CHF.